Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 18/20 | 0.55 |
| ▸ | PI4KA | P42356 | 1/20 | 0.45 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.45 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.45 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1192693 | 0.83 | MTNR1A (0.47) | ALDH1A1F2GLAHPGD | |
| SCHEMBL14537062 | 0.82 | MAP4K4 (0.49) | MAP4K4ALDH1A1 | |
| SCHEMBL535605 | 0.82 | ALDH1A1 (0.44) | ALDH1A1F2GLAHPGD | |
| SCHEMBL17660982 | 0.81 | MAP4K4 (0.57) | MAP4K4PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL30513773 | 0.81 | MAP4K4 (0.57) | MAP4K4PI4KAPI4K2BPI4K2API4KB | |
| Hydrochloric Acid SCHEMBL8309056 | 0.81 | ALDH1A1 (0.43) | ALDH1A1F2GLAHPGD | |
| SCHEMBL16199847 | 0.78 | ALDH1A1 (0.42) | ALDH1A1F2GLAHPGD | |
| SCHEMBL20016533 | 0.78 | IRAK4 (0.53) | MAP4K4PI4KAPI4K2BPI4K2API4KB | |
| Hydrochloric Acid SCHEMBL28325270 | 0.78 | MAP4K4 (0.74) | MAP4K4PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL30513775 | 0.76 | MAP4K4 (0.72) | MAP4K4PI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309563-B2 | Quinazoline derivatives useful as anti-tumor medicament | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2012-11-13 | — | — | US | disclosed |
| US-8044063-B2 | Quinazoline derivatives useful as anti-tumor medicament | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2011-10-25 | — | — | US | disclosed |
| US-20110245246-A1 | Quinazoline Derivatives Useful as Anti-Tumor Medicament | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2011-10-06 | — | — | US | disclosed |
| EP-2248806-A2 | Quinazoline derivatives as tyrosine kinase inhibitors | Shanghai Allist Pharmaceuticals, Inc. (CN) | 2010-11-10 | — | — | EP | disclosed |
| US-20080300248-A1 | Quinazoline Derivatives, Preparation Methods and Uses Thereof | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2008-12-04 | — | — | US | disclosed |
| EP-1990337-A1 | QUINAZOLINE DERIVATIVES,PREPARATION METHODS AND USES THEREOF | SHANGHAI ALLIST PHARMACEUTICAL., INC. (CN) | 2008-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245246-A1 | Quinazoline Derivatives Useful as Anti-Tumor Medicament | TP53, NQO2, TOP1 | MAP4K4 1354/4885PI4KA 3182/4885PI4K2B 4138/4885 |
| US-20080300248-A1 | Quinazoline Derivatives, Preparation Methods and Uses Thereof | NQO2, AQP3, AQP1 | MAP4K4 1547/4885PI4KA 2687/4885PI4K2B 3595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.